Nanotechnology approaches for global infectious diseases

Ameya R Kirtane^#^{1

2

3}, Malvika Verma^#^{1

4

5}, Paramesh Karandikar^{1

2}, Jennifer Furin⁶, Robert Langer^{1

2

5

7

8}, Giovanni Traverso^{9

10

11}

Affiliations

¹ David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.
² Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA.
³ Division of Gastroenterology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
⁴ Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA.
⁵ Tata Center for Technology and Design, Massachusetts Institute of Technology, Cambridge, MA, USA.
⁶ Department of Global Health and Social Medicine, Harvard Medical School, Boston, MA, USA.
⁷ Media Lab, Massachusetts Institute of Technology, Cambridge, MA, USA.
⁸ Institute of Medical Engineering and Science, Massachusetts Institute of Technology, Cambridge, MA, USA.
⁹ Division of Gastroenterology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. cgt20@mit.edu.
¹⁰ Tata Center for Technology and Design, Massachusetts Institute of Technology, Cambridge, MA, USA. cgt20@mit.edu.
¹¹ Department of Mechanical Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA. cgt20@mit.edu.

^# Contributed equally.

PMID: 33753915
DOI: 10.1038/s41565-021-00866-8

Review

Nanotechnology approaches for global infectious diseases

Ameya R Kirtane et al. Nat Nanotechnol. 2021 Apr.

. 2021 Apr;16(4):369-384.

doi: 10.1038/s41565-021-00866-8. Epub 2021 Mar 22.

Authors

Ameya R Kirtane^#^{1

2

3}, Malvika Verma^#^{1

4

5}, Paramesh Karandikar^{1

2}, Jennifer Furin⁶, Robert Langer^{1

2

5

7

8}, Giovanni Traverso^{9

10

11}

Affiliations

¹ David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.
² Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA.
³ Division of Gastroenterology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
⁴ Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA.
⁵ Tata Center for Technology and Design, Massachusetts Institute of Technology, Cambridge, MA, USA.
⁶ Department of Global Health and Social Medicine, Harvard Medical School, Boston, MA, USA.
⁷ Media Lab, Massachusetts Institute of Technology, Cambridge, MA, USA.
⁸ Institute of Medical Engineering and Science, Massachusetts Institute of Technology, Cambridge, MA, USA.
⁹ Division of Gastroenterology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. cgt20@mit.edu.
¹⁰ Tata Center for Technology and Design, Massachusetts Institute of Technology, Cambridge, MA, USA. cgt20@mit.edu.
¹¹ Department of Mechanical Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA. cgt20@mit.edu.

^# Contributed equally.

PMID: 33753915
DOI: 10.1038/s41565-021-00866-8

Abstract

Infectious diseases are a major driver of morbidity and mortality globally. Treatment of malaria, tuberculosis and human immunodeficiency virus infection are particularly challenging, as indicated by the ongoing transmission and high mortality associated with these diseases. The formulation of new and existing drugs in nano-sized carriers promises to overcome several challenges associated with the treatment of these diseases, including low on-target bioavailability, sub-therapeutic drug accumulation in microbial sanctuaries and reservoirs, and low patient adherence due to drug-related toxicities and extended therapeutic regimens. Further, nanocarriers can be used for formulating vaccines, which represent a major weapon in our fight against infectious diseases. Here we review the current burden of infectious diseases with a focus on major drivers of morbidity and mortality. We then highlight how nanotechnology could aid in improving existing treatment modalities. We summarize our progress so far and outline potential future directions to maximize the impact of nanotechnology on the global population.

PubMed Disclaimer

References

1. Roth, G. A. et al. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the global burden of disease Study 2017. Lancet 392, 1736–1788 (2018). - DOI
1. Kinch, M. S., Patridge, E., Plummer, M. & Hoyer, D. An analysis of FDA-approved drugs for infectious disease: antibacterial agents. Drug Discov. Today 19, 1283–1287 (2014). - DOI
1. Munita, J. M. & Arias, C. A. Mechanisms of antibiotic resistance. Microbiol. Spectrum 4, VMBF-0016-2015. (2016). - DOI
1. Sabaté, E. Adherence to Long-Term Therapy: Evidence for Action (WHO, 2003).
1. Pheage, T. Dying from Lack of Medicines (United Nations, 2016); https://www.un.org/africarenewal/magazine/december-2016-march-2017/dying...

Publication types

Actions
Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- Nature Publishing Group
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Nanotechnology approaches for global infectious diseases

Affiliations

Nanotechnology approaches for global infectious diseases

Authors

Affiliations

Abstract

References

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical